Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D09SGV
|
|||
Drug Name |
Daclatasvir
|
|||
Synonyms |
1009119-64-5; Daclatasvir (BMS-790052); 1214735-16-6; CHEBI:82977; C40H50N8O6; methyl N-[(1S)-1-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methyl-butanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidine-1-carbonyl]-2-methyl-propyl]carbamate; Daclatasvir (USAN); cc-39; Daclatasvir BMS 790052; MLS006011140; SCHEMBL2756027; CHEMBL2023898; SCHEMBL17897804; KS-00000XPC; EX-A410
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Hepatitis C virus infection [ICD-11: 1E51.1; ICD-10: B18.2] | Approved | [1] | |
Company |
Bristol-Myers Squibb
|
|||
Structure |
Download2D MOL
|
|||
Formula |
C40H50N8O6
|
|||
Canonical SMILES |
CC(C)C(C(=O)N1CCCC1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CN=C(N5)C6CCCN6C(=O)C(C(C)C)NC(=O)OC)NC(=O)OC
|
|||
InChI |
1S/C40H50N8O6/c1-23(2)33(45-39(51)53-5)37(49)47-19-7-9-31(47)35-41-21-29(43-35)27-15-11-25(12-16-27)26-13-17-28(18-14-26)30-22-42-36(44-30)32-10-8-20-48(32)38(50)34(24(3)4)46-40(52)54-6/h11-18,21-24,31-34H,7-10,19-20H2,1-6H3,(H,41,43)(H,42,44)(H,45,51)(H,46,52)/t31-,32-,33-,34-/m0/s1
|
|||
InChIKey |
FKRSSPOQAMALKA-CUPIEXAXSA-N
|
|||
CAS Number |
CAS 1009119-64-5
|
|||
PubChem Compound ID | ||||
ChEBI ID |
CHEBI:82977
|
|||
ADReCS Drug ID | BADD_D00569 |
Drug Resistance Mutation (DRM) | Top | |||
---|---|---|---|---|
DRM | DRM Info |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Hepatitis C virus Non-structural 5A (HCV NS5A) | Target Info | Inhibitor | [2] |
References | Top | |||
---|---|---|---|---|
REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | |||
REF 2 | 2011 Pipeline of Bristol-Myers Squibb. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.